September 27, 2026 · Platform news · Cancer screening

How the Panel Voted

When the FDA advisory panel delivered its Galleri vote outcome on September 23, 2026, the committee recommended approval while revealing sharp divisions over the clinical data. The Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee to the Food and Drug Administration (FDA) evaluated three separate questions.

Ten voting members participated in the meeting. On safety, the panel voted 10 to 0 in support of Galleri.

On effectiveness, the committee split, voting 6 in favor and 4 opposed. On benefit-risk, the panel voted 7 in favor and 2 opposed, with 1 member abstaining.

According to reporting from STAT News, the benefit-risk question asked panelists whether "the benefits of Galleri outweigh the risk for use in patients who meet the criteria specified in the proposed indication." The proposed indication covers screening for the early detection of multiple types of cancer in adults aged 50 years and older.

A favorable panel vote is a recommendation. It is not an approval. The FDA takes the advisory committee's recommendations into consideration, but federal regulators are not bound by them.

GRAIL submitted its premarket approval (PMA) application on January 29, 2026. The test remains unapproved while the agency completes its review.

The short version

The panel gave Galleri a majority on every ballot, but the three tallies are not equally strong. Safety was unanimous at 10 to 0. A blood draw carries little physical risk, so that vote was never in doubt. Effectiveness split 6 to 4, the narrowest of the three. That question was whether Galleri works, and a reader tracking this review should weigh the 6 to 4 more heavily than the 10 to 0.

Why the Effectiveness Vote Was the Close One

The 6 to 4 vote on effectiveness was the narrowest outcome of the meeting. That split centered on clinical evidence from the NHS-Galleri trial conducted with the National Health Service (NHS) in England.

The randomized NHS-Galleri trial did not meet its primary endpoint. The trial did not show a reduction in combined late-stage cancers overall across the study population.

At the same time, the trial demonstrated a reduction in stage IV diagnoses specifically, as reported by Clinical Trial Vanguard. That divergence between a flat overall late-stage composite and a drop in stage IV cases created conflicting interpretations of the data.

When a trial misses its primary composite endpoint, the study has not proved its main screening goal. A reduction in stage IV diagnoses indicates that the test detected some aggressive tumors before progression. Those two findings explain why a negative vote on effectiveness was a defensible position rather than procedural opposition.

Six members voted that the effectiveness evidence was sufficient. Four voted that it was not. No account of how any individual member reasoned has been published.

What the Trial Evidence Actually Showed

Two clinical trials informed GRAIL's premarket approval application: PATHFINDER 2 in North America and NHS-Galleri in England, as reported by The ASCO Post. The Galleri test uses next-generation sequencing to evaluate methylation patterns in cell-free deoxyribonucleic acid (DNA) from a blood sample.

According to a press release from GRAIL, the test detected approximately four to seven times more cancers compared to standard of care alone. GRAIL also reported that most cancers were found at earlier stages, with a low false-positive rate and high accuracy in predicting cancer signal origin.

Following the panel vote, GRAIL Chief Executive Officer Josh Ofman stated: "Today's vote reinforces the strength of Galleri's clinical evidence." Additional data from PATHFINDER 2 showed a 6.5-fold increase in cancer detection when Galleri was added to standard screening, according to Clinical Trial Vanguard.

The ASCO Post noted that any Galleri result should be followed by a diagnostic workup by a qualified health-care professional.

What Happens Next at the FDA

The advisory panel meeting is a consultative milestone rather than the final regulatory step. GRAIL submitted its premarket approval application on January 29, 2026, and federal regulators convened the panel to evaluate the trial record.

The FDA is not bound by the committee's recommendations, though it takes them into consideration. Agency reviewers will weigh the 10 to 0 safety vote, the 7 to 2 benefit-risk recommendation, and the 6 to 4 effectiveness split. Regulators evaluate those tallies alongside the underlying trial datasets.

GRAIL reports that an official FDA decision on the application is expected in the coming months. No specific calendar date has been published by the agency or the company.

What This Changes for Someone Considering Galleri Today

The panel vote changes nothing about Galleri's regulatory status. The test is still not approved by the FDA, and the agency's decision on the premarket approval application is still pending.

Anyone evaluating the test must weigh the split verdict in the clinical trial data. Safety is not in dispute, as the 10 to 0 vote confirmed minimal direct physical risk from a blood sample. The effectiveness evidence remains debated because the primary endpoint of reducing combined late-stage cancers was not met.

Any positive result from Galleri requires a diagnostic workup by a qualified health-care professional to locate and evaluate the suspected tumor. The test does not diagnose cancer on its own.

Our Galleri review details current testing logistics, ordering requirements, and pricing. To see how Galleri compares with alternative testing platforms, our guide to the best multi-cancer screening blood tests evaluates the broader category.

What Would Change This Read

A formal regulatory ruling from the FDA would change this assessment immediately. An approval would settle the test's regulatory standing under the proposed indication for adults aged 50 years and older. Until the agency acts, the test remains unapproved.

Full peer-reviewed publication of the NHS-Galleri trial data would also clarify the clinical picture. Reporting on the meeting establishes that the trial missed its primary endpoint on combined late-stage cancers while reducing stage IV diagnoses specifically.

A breakdown by individual cancer type would show how the stage IV reduction and the flat overall late-stage rate fit together. Until the FDA rules, the 6 to 4 split among the panel's 10 voting members is the closest thing to a verdict on the evidence.

Related Coverage

We covered this meeting before it sat, in our preview of the Galleri FDA advisory panel. On the payer side, our report on Galleri employer health plan coverage looks at a Michigan health plan that added the test. Newer diagnostics coverage sits in our health platforms directory and our main news index.

Sources

  • GRAIL, "FDA Advisory Committee Votes in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test," press release, September 23, 2026, grail.com (accessed September 27, 2026). Source for the September 23, 2026 meeting date, the Molecular and Clinical Genetics Devices Panel name, the 10 voting members, all three vote tallies (10 to 0 on safety, 7 to 2 with 1 abstention on benefit-risk, 6 to 4 on effectiveness), the proposed indication for adults aged 50 and older, the January 29, 2026 PMA submission date, the detection of four to seven times more cancers claim, the earlier-stage detection claim, the low false-positive and origin accuracy claims, the Josh Ofman quotation, that the FDA is not bound by recommendations, and that a decision is expected in the coming months.
  • STAT News, "FDA advisory panel recommends approval of Grail's Galleri multi-cancer blood test," September 23, 2026, statnews.com (accessed September 27, 2026). Source for the verbatim wording of the benefit-risk question, independent confirmation of the three vote counts, and that the FDA is not obliged to follow panel advice.
  • The ASCO Post, "FDA Advisory Committee Votes in Favor of Approval of Multi-Cancer Early Detection Test," September 2026, ascopost.com (accessed September 27, 2026). Source for the next-generation sequencing and cell-free DNA methylation mechanism, PATHFINDER 2 and NHS-Galleri as the trials informing the application, and the requirement that a Galleri result be followed by a diagnostic workup by a qualified health-care professional.
  • Clinical Trial Vanguard, "FDA Advisory Panel Votes 7-2 to Support Galleri Multi-Cancer Blood Test," September 2026, clinicaltrialvanguard.com (accessed September 27, 2026). Source for the NHS-Galleri primary endpoint miss on combined late-stage cancers, the reduction in stage IV diagnoses specifically, and the 6.5-fold increase in cancer detection reported in PATHFINDER 2.

Frequently Asked Questions

Is Galleri FDA approved now?

No. Galleri is not approved by the Food and Drug Administration (FDA). On September 23, 2026, an FDA advisory committee voted in favor of the test across three separate questions, including a 7 to 2 vote on benefit-risk. That vote is a recommendation for the agency to review. The FDA considers the panel's recommendation when evaluating GRAIL's premarket approval (PMA) application, but federal regulators are not bound by the panel's vote and have not issued an approval decision.

What were the three FDA panel votes on Galleri?

The Molecular and Clinical Genetics Devices Panel voted on safety, effectiveness, and benefit-risk. On safety, the panel voted 10 to 0 that Galleri is safe. On effectiveness, the panel voted 6 to 4 that there is reasonable assurance the test is effective. On benefit-risk, the panel voted 7 to 2, with 1 member abstaining, that the benefits outweigh the risks for adults aged 50 and older.

Why did only 6 of 10 panel members support Galleri's effectiveness?

The effectiveness vote divided the panel 6 to 4 following clinical data from the NHS-Galleri trial in England. In that randomized study, Galleri did not meet its primary endpoint of reducing combined late-stage cancers overall. The trial did show a reduction in stage IV cancer diagnoses specifically. That divergence between a flat overall late-stage composite and a reduction in stage IV diagnoses left room for differing assessments of whether the trial proved effectiveness.

Did the NHS-Galleri trial fail?

The NHS-Galleri randomized trial did not meet its primary endpoint, which was a reduction in combined late-stage cancers overall. At the same time, trial data showed a reduction in stage IV diagnoses specifically. The result was mixed: the study missed its primary measure of overall late-stage reduction while still showing an effect on stage IV cancer detection.

When will the FDA make its final decision on Galleri?

The FDA has not published a specific calendar date for its decision. Public announcements from GRAIL indicate that an official regulatory determination on the premarket approval application is expected in the coming months. Regulators are reviewing the trial evidence alongside the advisory panel's recommendations.

Should I get a Galleri test while the FDA decision is pending?

A decision to order Galleri is an individual medical choice that requires a discussion with a healthcare provider. The indication GRAIL proposed covers screening adults aged 50 years and older for the early detection of multiple cancer types. Any positive result requires a diagnostic workup by a qualified health-care professional. Our standing review covers current test logistics and considerations in detail.